GSK (LON:GSK – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported GBX 54.60 EPS for the quarter, Digital Look Earnings reports. GSK had a return on equity of 28.35% and a net margin of 14.52%. The firm had revenue of GBX 888.70 billion during the quarter.
GSK Stock Down 3.8%
Shares of GSK stock traded down GBX 72.50 during trading on Wednesday, reaching GBX 1,851. The company’s stock had a trading volume of 52,013,336 shares, compared to its average volume of 12,515,744. GSK has a 1-year low of GBX 1,664 and a 1-year high of GBX 2,282. The stock’s 50-day moving average price is GBX 1,850.33 and its 200 day moving average price is GBX 1,949.81. The company has a market capitalization of £74.17 billion, a price-to-earnings ratio of 15.71, a P/E/G ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73.
Insider Activity
In other news, insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were purchased at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal acquired 637 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The shares were bought at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. Insiders bought a total of 2,151 shares of company stock valued at $6,021,921 in the last quarter. Company insiders own 0.20% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Research Report on GSK
Key GSK News
Here are the key news stories impacting GSK this week:
- Positive Sentiment: GSK reported third-quarter earnings of 54.60p per share and revenue of approximately £8.89 billion, topping expectations. Growth in specialty medicines and recently launched products supported the performance. GSK tops third-quarter estimates as new medicines drive growth, keeps outlook
- Positive Sentiment: The company reaffirmed its 2026 financial outlook, suggesting management remains confident in underlying operating momentum despite ongoing cost pressures. GSK delivers Q3 earnings beat, reaffirms 2026 outlook
- Positive Sentiment: GSK plans to nearly double the number of cancer medicines in clinical trials next year. The expansion could improve the company’s long-term oncology growth prospects, although the programs will require substantial investment and carry development risk. GSK to nearly double cancer drugs in trials, WSJ reports
- Positive Sentiment: Pipeline news also provided support: GSK’s rectal-cancer drug met its Phase 2 primary objective, while a bone-cancer treatment developed with Hansoh delayed disease progression in a late-stage Chinese study. GSK’s Rectal Cancer Drug Meets Primary Objective in Phase 2 Trial
- Neutral Sentiment: An executive disclosed an acquisition of GSK American depositary shares, a signal of insider confidence but a transaction unlikely to materially affect valuation. GSK Reports October Executive Notional ADS Acquisition on NYSE
- Negative Sentiment: A £328 million restructuring charge reduced reported profit. Investors may also be disappointed that GSK maintained, rather than raised, its outlook following the earnings beat. GSK keeps guidance as specialty drugs power sales, but restructuring charge dents profit
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Featured Stories
- Five stocks we like better than GSK
- Welltower’s Strong Earnings Couldn’t Stop the Sell-Off—What’s Missing?
- Sherwin-Williams Remains Evergreen in a Frozen Housing Market
- Palantir’s Q3 Bar Is Higher Than It Looks: 3 Numbers to Watch
- Johnson Controls Beats the Heat in AI Data Centers
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
